Hypoxia Within the Glioblastoma Tumor Microenvironment: a Master Saboteur of Novel Treatments

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2024 Jul 12

PMID 38994360

Authors

Lisa Feldman

Affiliations

Soon will be listed here.

Abstract

Glioblastoma (GBM) tumors are the most aggressive primary brain tumors in adults that, despite maximum treatment, carry a dismal prognosis. GBM tumors exhibit tissue hypoxia, which promotes tumor aggressiveness and maintenance of glioma stem cells and creates an overall immunosuppressive landscape. This article reviews how hypoxic conditions overlap with inflammatory responses, favoring the proliferation of immunosuppressive cells and inhibiting cytotoxic T cell development. Immunotherapies, including vaccines, immune checkpoint inhibitors, and CAR-T cell therapy, represent promising avenues for GBM treatment. However, challenges such as tumor heterogeneity, immunosuppressive TME, and BBB restrictiveness hinder their effectiveness. Strategies to address these challenges, including combination therapies and targeting hypoxia, are actively being explored to improve outcomes for GBM patients. Targeting hypoxia in combination with immunotherapy represents a potential strategy to enhance treatment efficacy.

Citing Articles

It's all downstream from here: RTK/Raf/MEK/ERK pathway resistance mechanisms in glioblastoma.

Yakubov R, Kaloti R, Persaud P, McCracken A, Zadeh G, Bunda S J Neurooncol. 2025; .

PMID: 39821893 DOI: 10.1007/s11060-024-04930-w.

Towards Effective Treatment of Glioblastoma: The Role of Combination Therapies and the Potential of Phytotherapy and Micotherapy.

Gaiaschi L, Bottone M, De Luca F Curr Issues Mol Biol. 2024; 46(12):14324-14350.

PMID: 39727987 PMC: 11674107. DOI: 10.3390/cimb46120859.

Advancements in nanotheranostics for glioma therapy.

Sahoo L, Paikray S, Tripathy N, Fernandes D, Dilnawaz F Naunyn Schmiedebergs Arch Pharmacol. 2024; .

PMID: 39480526 DOI: 10.1007/s00210-024-03559-w.

Recent Treatment Strategies and Molecular Pathways in Resistance Mechanisms of Antiangiogenic Therapies in Glioblastoma.

Rahman M, Ali M Cancers (Basel). 2024; 16(17).

PMID: 39272834 PMC: 11394361. DOI: 10.3390/cancers16172975.

Tumor perfusion enhancement by focus ultrasound-induced blood-brain barrier opening to potentiate anti-PD-1 immunotherapy of glioma.

Shan H, Zheng G, Bao S, Yang H, Shrestha U, Li G Transl Oncol. 2024; 49:102115.

PMID: 39217852 PMC: 11402623. DOI: 10.1016/j.tranon.2024.102115.

References

Winograd E, Ciesielski M, Fenstermaker R . Novel vaccines for glioblastoma: clinical update and perspective. Immunotherapy. 2016; 8(11):1293-1308. PMC: 5619015. DOI: 10.2217/imt-2016-0059. View

Morimoto T, Nakazawa T, Maeoka R, Nakagawa I, Tsujimura T, Matsuda R . Natural Killer Cell-Based Immunotherapy against Glioblastoma. Int J Mol Sci. 2023; 24(3). PMC: 9916747. DOI: 10.3390/ijms24032111. View

Cagney D, Martin A, Catalano P, Redig A, Lin N, Lee E . Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study. Neuro Oncol. 2017; 19(11):1511-1521. PMC: 5737512. DOI: 10.1093/neuonc/nox077. View

Bao S, Wu Q, McLendon R, Hao Y, Shi Q, Hjelmeland A . Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006; 444(7120):756-60. DOI: 10.1038/nature05236. View

Chen H, Lin L, Wang M, Lee S, Tsai M, Tsai C . Musashi-1 regulates AKT-derived IL-6 autocrinal/paracrinal malignancy and chemoresistance in glioblastoma. Oncotarget. 2016; 7(27):42485-42501. PMC: 5173150. DOI: 10.18632/oncotarget.9890. View

Maude S, Laetsch T, Buechner J, Rives S, Boyer M, Bittencourt H . Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018; 378(5):439-448. PMC: 5996391. DOI: 10.1056/NEJMoa1709866. View

FEINBERG B, Kurzrock R, Talpaz M, Blick M, Saks S, Gutterman J . A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients. J Clin Oncol. 1988; 6(8):1328-34. DOI: 10.1200/JCO.1988.6.8.1328. View

Talaei S, Mellatyar H, Asadi A, Akbarzadeh A, Sheervalilou R, Zarghami N . Spotlight on 17-AAG as an Hsp90 inhibitor for molecular targeted cancer treatment. Chem Biol Drug Des. 2019; 93(5):760-786. DOI: 10.1111/cbdd.13486. View

Beavis P, Henderson M, Giuffrida L, Mills J, Sek K, Cross R . Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy. J Clin Invest. 2017; 127(3):929-941. PMC: 5330718. DOI: 10.1172/JCI89455. View

10.

Ghouzlani A, Kandoussi S, Tall M, Reddy K, Rafii S, Badou A . Immune Checkpoint Inhibitors in Human Glioma Microenvironment. Front Immunol. 2021; 12:679425. PMC: 8301219. DOI: 10.3389/fimmu.2021.679425. View

11.

Lubin J, Zhang R, Kuo J . Zika Virus has Oncolytic Activity Against Glioblastoma Stem Cells. Neurosurgery. 2018; 82(5):E113-E114. PMC: 6257021. DOI: 10.1093/neuros/nyy047. View

12.

Wang Q, He Z, Huang M, Liu T, Wang Y, Xu H . Vascular niche IL-6 induces alternative macrophage activation in glioblastoma through HIF-2α. Nat Commun. 2018; 9(1):559. PMC: 5805734. DOI: 10.1038/s41467-018-03050-0. View

13.

Schreiber R, Old L, Smyth M . Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011; 331(6024):1565-70. DOI: 10.1126/science.1203486. View

14.

Tsakiridis T, Pond G, Wright J, Ellis P, Ahmed N, Abdulkarim B . Metformin in Combination With Chemoradiotherapy in Locally Advanced Non-Small Cell Lung Cancer: The OCOG-ALMERA Randomized Clinical Trial. JAMA Oncol. 2021; 7(9):1333-1341. PMC: 8323053. DOI: 10.1001/jamaoncol.2021.2328. View

15.

Fan X, Xiong Y, Wang Y . A reignited debate over the cell(s) of origin for glioblastoma and its clinical implications. Front Med. 2019; 13(5):531-539. DOI: 10.1007/s11684-019-0700-1. View

16.

Li R, Li G, Deng L, Liu Q, Dai J, Shen J . IL-6 augments the invasiveness of U87MG human glioblastoma multiforme cells via up-regulation of MMP-2 and fascin-1. Oncol Rep. 2010; 23(6):1553-9. DOI: 10.3892/or_00000795. View

17.

Chafe S, McDonald P, Saberi S, Nemirovsky O, Venkateswaran G, Burugu S . Targeting Hypoxia-Induced Carbonic Anhydrase IX Enhances Immune-Checkpoint Blockade Locally and Systemically. Cancer Immunol Res. 2019; 7(7):1064-1078. DOI: 10.1158/2326-6066.CIR-18-0657. View

18.

Xuan W, Khan F, James C, Heimberger A, Lesniak M, Chen P . Circadian regulation of cancer cell and tumor microenvironment crosstalk. Trends Cell Biol. 2021; 31(11):940-950. PMC: 8526375. DOI: 10.1016/j.tcb.2021.06.008. View

19.

Jayaprakash P, Ai M, Liu A, Budhani P, Bartkowiak T, Sheng J . Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy. J Clin Invest. 2018; 128(11):5137-5149. PMC: 6205399. DOI: 10.1172/JCI96268. View

20.

Woroniecka K, Chongsathidkiet P, Rhodin K, Kemeny H, Dechant C, Farber S . T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma. Clin Cancer Res. 2018; 24(17):4175-4186. PMC: 6081269. DOI: 10.1158/1078-0432.CCR-17-1846. View